glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Effects of Once-Weekly on Disease by KDIGO Risk Category in the SUSTAIN 6 Cardiovascular, Kidney, and Safety Outcomes – Association of glucagon-like peptide-1 receptor

For many, the risks are vastly outweighed by the benefits: The medication is FDA approved and considered safe to use for weight loss for most people

Chitra Gantra explains that she's in favor of prescribing GLP-1s to adults until they're age 65 (via American Academy of Medical Colleges)

The financial sustainability of long-term use is a consideration

Inject the dose under the skin (subcutaneously) of the thigh, abdomen, or upper arm

Does your dull complexion make you feel uncomfortable

And I think that thats where some of the research is gonna have to go in the future is to find out whats the combination, combinatorial effect of the GLP-1s with a little bit of activity